Polaris Group
TWSE:6550
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
43.1
75.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Polaris Group
Operating Margin
Polaris Group
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | KY |
| Market Cap | 34.3B TWD |
| Operating Margin |
-5 646%
|
| Country | FR |
| Market Cap | 6T USD |
| Operating Margin |
-17 527%
|
| Country | US |
| Market Cap | 314.6B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 141.2B USD |
| Operating Margin |
19%
|
| Country | US |
| Market Cap | 117.3B USD |
| Operating Margin |
38%
|
| Country | US |
| Market Cap | 105.4B USD |
| Operating Margin |
40%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Operating Margin |
-370%
|
| Country | AU |
| Market Cap | 136.4B AUD |
| Operating Margin |
26%
|
| Country | US |
| Market Cap | 78.4B USD |
| Operating Margin |
30%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Operating Margin |
-33%
|
| Country | NL |
| Market Cap | 36.2B EUR |
| Operating Margin |
-22%
|
Polaris Group
Glance View
In the competitive realm of biotechnology, Polaris Group has carved out a niche by focusing on the research and development of novel cancer therapeutics. Founded with a mission to bring innovative treatments to patients with unmet medical needs, the company has strategically positioned itself within the oncology sector. Polaris Group's approach is to harness the power of immunotherapy, aiming to develop solutions that enhance the immune system's ability to target and destroy cancer cells. This ambitious pursuit leverages cutting-edge technologies and a robust pipeline of investigational drugs, with particular emphasis on engineered drug compounds that can target specific pathways essential for cancer cell survival and proliferation. The key to Polaris Group's financial ecosystem is its revenue generation through strategic partnerships and collaborations with major pharmaceutical companies. By partnering with larger firms, Polaris is able to co-develop its breakthrough therapies, thus sharing the burden of development costs and risks. This model not only facilitates the advancement of their drug candidates but also offers potential revenue streams from milestone payments and royalties upon successful commercialization. Polaris’s business model underscores the significance of collaboration in biotech, where innovative ideas need both scientific expertise and considerable financial backing to transform into viable market solutions, ultimately contributing to the company's profitability and sustained growth in the competitive pharmaceutical landscape.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Polaris Group's most recent financial statements, the company has Operating Margin of -5 645.8%.
You don't have any saved screeners yet